drugset
drugset / Trial / NCT04328766

Pharmacokinetic Interaction Between DWP14012 and DWC202005 in Healthy Volunteers

NCT04328766 ↗

Phase 1 Completed 36 enrolled Daewoong Pharmaceutical Co. LTD.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

An open-label, multiple-dose clinical trial to evaluate the safety/tolerability and pharmacokinetic interaction between DWP14012 and DWC202005 in healthy volunteers

Timeline

Start
2020-09-06
Primary completion
2020-11-21
Completion
2020-11-21

Drugs

EvaluationDrugModalityDoseRoute
Subject ABEPRAZAN Small molecule — Oral
Subject DWC202005 Unknown — —

Indications

No indication recorded.